Cardiovascular Effects of Incretin-Based Therapies.
Farmington, United States. In Annu Rev Med, Feb 2016
This article reviews the most recent CV outcome trials of the DPP-4 inhibitors (SAVOR-TIMI 53, EXAMINE, and TECOS) as evidence that the incretin-based therapies have acceptable CV safety profiles for patients with T2DM.
Dual pathway therapy in acute coronary syndrome.
Freiburg, Germany. In J Thromb Thrombolysis, Jan 2016
In contrast, the ATLAS ACS2 TIMI-51 trial interrogating the oral factor Xa inhibitor rivaroxaban in a low dose regimen showed significant reduction of cardiovascular events as well as total mortality.
Lorcaserin Hcl for the treatment of obesity.
United States. In Expert Opin Pharmacother, Nov 2015
The results of the ongoing cardiovascular outcomes trial (CAMELLIA TIMI 61) will determine the role of lorcaserin in primary prevention of diabetes in overweight/obese individuals and its use in the high-risk population of patients with established cardiovascular disease or multiple cardiovascular risk factors.
On-treatment platelet reactivity: State of the art and perspectives.
Florence, Italy. In Vascul Pharmacol, Nov 2015
To overcome the limitation of clopidogrel, new antiplatelet agents (prasugrel and ticagrelor) were developed and the demonstration of their superiority over clopidogrel was obtained in the two randomized trials, TRITON TIMI 38 and PLATO.